How SLU-PP-332 Works: Mechanism and Pharmacology
How SLU-PP-332 works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.
- Class
- ERR agonist (not a peptide)
- FDA status
- Not approved
- research chemical
- Routes studied
- None stated
- PubMed search, 11 Oct 2026
- Half-life
- [pending]
- by route, with source
How long it acts
No published half-life found for SLU-PP-332 (PubMed search, 11 Oct 2026)
Full detail, including drug-testing windows, is on the SLU-PP-332 half-life page.
The receptor it targets
The first report describes SLU-PP-332 as an ERR pan agonist that targets all three receptors, with highest potency for ERR alpha.[4]
In mice the endurance effect required ERR alpha activation.[4]
In the heart-failure model the main mediator was ERR gamma, so the receptor subtype that matters depends on the tissue.[5]
Downstream pathways in mice and cells
In aged mice, the kidney effects ran through the cGAS-STING and STAT3 signalling pathways.[6]
In cultured human muscle cells from inactive women, the compound raised SIRT1, PGC-1α and ERRα and lowered NOX4.[7]
A review of the preclinical literature summarises a gene expression program like acute aerobic exercise that drives fatty acid oxidation.[8]
Exposure and what is unknown
The first report states that the compound has pharmacokinetic properties sufficient for use as an in vivo tool; no oral bioavailability value is cached.[4]
In human liver S9 fractions the compound yielded 22 metabolites in the lab, which is not data from a dosed person.[9]
Related peptides
Common questions
How long does SLU-PP-332 act in the body?
We found no published half-life for SLU-PP-332 (PubMed search, 11 Oct 2026), so how long it acts is unknown.
Is SLU-PP-332 an ERR agonist?
Yes: it is reported as a synthetic agonist of all three estrogen-related receptors.[4]
Does SLU-PP-332 work?
It works in mouse models; the review calls for human trials.[8]
More on SLU-PP-332
Sources
- 1PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 4Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
- 5Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.Circulation · 2024PMID 37961903Accessed 2 Oct 2026
- 6Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.The American journal of pathology · 2023PMID 37717940Accessed 2 Oct 2026
- 7Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026
- 8[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
- 9Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026
Found an error? Report a correction.